Related Experiment Videos
BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics
1Dana-Farber Cancer Institute, 1 Jimmy Fund Way, Boston, Massachusetts 02115, USA. anthony_letai@dfci.harvard.edu
Abstract:
It is likely that most, if not all, cancer cells possess a mechanism for opposing programmed cell death, or apoptosis. One mechanism often used by cancer cells to escape apoptosis is the overexpression of B cell leukaemia/lymphoma-2 protein (BCL-2) or related antiapoptotic proteins. Inhibiting BCL-2, therefore, is an anticancer strategy worthy of attention. BCL-2 homology 3 (BH3) domains are alpha-helical segments found in BCL-2 family member proteins. In pro-apoptotic members, the BH3 domain is necessary for pro-apoptotic function. It has been shown that short peptides derived from the BH3 region possess intrinsic pro-death activity. Furthermore, certain peptides of this group exert their pro-death function by specifically binding BCL-2 and opposing BCL-2's antideath function. Therefore, BH3 domains are prototype BCL-2 inhibitors. Mimetics of BH3 domains, whether derived from peptides or small molecules, have promise as cancer therapeutics.
Insights
Cancer cells evade apoptosis using antiapoptotic proteins like BCL-2. BH3 domains and their mimetics show promise as cancer therapeutics by inhibiting these proteins.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Most cancer cells evade programmed cell death (apoptosis).
- Overexpression of BCL-2 (B cell leukaemia/lymphoma-2) and related proteins is a common mechanism for cancer cells to escape apoptosis.
- Inhibiting BCL-2 is a potential anticancer strategy.
Purpose of the Study:
- To explore the potential of BCL-2 homology 3 (BH3) domains and their mimetics as anticancer therapeutics.
- To investigate the role of BH3 domains in apoptosis and their interaction with BCL-2.
Main Methods:
- Analysis of BCL-2 family proteins and their functional domains.
- Investigation of short peptides derived from BH3 regions.
- Assessment of BH3 domain mimetics (peptides and small molecules) as BCL-2 inhibitors.
Main Results:
- BH3 domains are essential for the pro-apoptotic function of BCL-2 family members.
- Short peptides derived from BH3 regions exhibit intrinsic pro-death activity.
- Specific BH3-derived peptides bind to BCL-2, counteracting its anti-death function, thus acting as prototype BCL-2 inhibitors.
Conclusions:
- BH3 domains serve as natural inhibitors of BCL-2.
- BH3 mimetics, including peptides and small molecules, represent a promising therapeutic strategy for cancer treatment by targeting BCL-2.